Deciphering Mechanisms of Hepatic Immunity Governing Pancreatic Cancer Liver Metastasis

解读肝脏免疫控制胰腺癌肝转移的机制

• 批准号: 10750243
• 负责人: Michael B Kastan
• 金额: $ 20.13万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10750243
• 关键词: Achievement; Arts; Authorization documentation; Award; Basic Science; Businesses; Cancer Burden; Cancer Center Support Grant; Cancer Patient; Cancer Science; Caring; Catchment Area; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Communities; Community Health; Community Outreach; Complex; Development; Direct Costs; Discipline of Nursing; Duke Comprehensive Cancer Center; Education; Engineering; Enrollment; Environment; Faculty; Faculty Recruitment; Fellowship; Funding; Future; Goals; Grant; Health; Health system; Hepatic; Immunity; Infrastructure; Interdisciplinary Study; Intervention; Investigation; Investments; Laboratories; Leadership; Link; Malignant Neoplasms; Malignant neoplasm of pancreas; Medicine; Metastatic Neoplasm to the Liver; Mission; Oncology; Paper; Patient Care; Patients; Peer Review; Pilot Projects; Population; Population Research; Population Sciences; Process; Public Policy; Publishing; Recommendation; Research Activity; Research Infrastructure; Research Personnel; Research Technics; Resource Allocation; Resource Sharing; Schools; Science; Scientist; Series; Signal Transduction; Strategic Planning; Structure; Testing; Therapeutic; Time; Training; Training and Education; Translational Research; Translations; Universities; University Hospitals; Work; anticancer research; authority; cancer care; cancer genomics; career development; clinical care; community based participatory research; community engagement; cost; design; health disparity; innovation; medical schools; member; multidisciplinary; new technology; next generation; novel; outpatient facility; population based; programs; recruit; therapeutic development; therapeutic evaluation; training opportunity; translational study

PROJECT SUMMARY/ABSTRACT – OVERALL The Duke Comprehensive Cancer Center was founded as a matrix center within the Duke University School of Medicine in 1972 and the Duke Cancer Institute (DCI) was created as a new administrative entity within Duke Health in October 2010, with authority and responsibility for all cancer-related activities at Duke University and in the Duke University Health System. The DCI was started with significant investments from Duke Health, including a new $243M clinical care outpatient facility, over $60 million of new funds available to support new initiatives, and a commitment for ongoing annual investment by the Duke Health System. DCI faculty include well-established and funded experts spanning the full spectrum of cancer research fields, from intracellular signaling to cancer genomics to therapeutic development and testing to population science. DCI programmatic activities support the career development of the next generation of cancer experts and provide platforms for multi-disciplinary scientific teams to develop and test new hypotheses. During the most recent funding period, the DCI structure has continued to evolve and mature, currently consisting of 304 members from 34 departments within 7 schools at Duke University (Medicine, Nursing, Arts and Sciences, Engineering, Public Policy, Environment, and Business) and organized as 8 multi-disciplinary research programs (2 basic discovery, 1 population science, and 5 translational/clinical) whose work is supported by 14 Shared Resources (8 lab-based and 6 supporting translational/clinical/population research activities). In addition to Program and Shared Resource leaders, DCI senior leadership, which includes an Executive Director, Deputy Director, 7 Associate Directors, and 8 other key leaders, provides oversight and direction of DCI initiatives. DCI members are currently supported by over $111M of external cancer-related grant support (direct costs), over $63M of which is peer- reviewed, including 32 peer-reviewed, multi-investigator grants (involving 81 subprojects/cores) and 61 training and fellowship awards. DCI members published over 5,750 cancer-focused papers during the past funding period, ~40% of which represent collaborative efforts between DCI investigators. On average, ~7,000 new cancer patients are seen each year at the Duke University Hospital. In 2018, DCI Programs enrolled over 4,000 patients on clinical trials, including nearly 2,000 interventional accruals and 770 therapeutic accruals. DCI is heavily engaged in both community outreach/engagement and educating the next generation of cancer clinicians and scientists. Duke Health support of the DCI included a total of over $65M of additional investment in the most recent funding period, including support for recruitment, retention, and protected academic time for DCI faculty. The DCI completed an extensive 5-year Strategic Planning process, identifying strategic goals and priorities that enable the DCI mission to “Discover, Develop, and Deliver the future of cancer care…now”, resulting in a series of discrete recommendations that are serving as a guide for determining current and future resource allocation, recruiting priorities, and infrastructure changes required to achieve DCI goals.

项目摘要/摘要--总体 杜克综合癌症中心是作为杜克大学学院内的一个矩阵中心而成立的 医学和杜克癌症研究所(DCI)于1972年成立，作为杜克大学内部的一个新的行政实体 2010年10月，负责杜克大学所有与癌症有关的活动 在杜克大学医疗系统中。DCI是在杜克健康公司的大量投资下成立的， 包括2.43亿美元的新临床护理门诊设施，6000多万美元的新资金可用于支持新的 倡议，以及对杜克卫生系统持续年度投资的承诺。DCI教职员工包括 久负盛名、资金雄厚的专家，横跨从细胞内到细胞内的所有癌症研究领域 向癌症基因组学发出信号，向治疗发展发出信号，向人口科学发出测试信号。DCI程序化 活动支持下一代癌症专家的职业发展，并为 多学科科学团队来开发和测试新的假说。在最近的筹资期间， DCI的结构不断发展和成熟，目前由来自34个部门的304名成员组成 杜克大学7所学院(医学、护理、文理、工程、公共政策、 环境和商业)，并组织为8个多学科研究项目(2个基本发现，1个 人口科学和5个翻译/临床)，他们的工作得到14个共享资源的支持(8个基于实验室 和6支持翻译/临床/人口研究活动)。除了计划和共享之外 资源领导，DCI高级领导，包括1名执行主任、副主任、7名助理 董事和其他8名主要领导对DCI倡议提供监督和指导。DCI成员目前 由超过1.11亿美元的外部癌症相关赠款支持(直接费用)，其中超过6300万美元是同行- 经审查，包括32项经同行审查的多名调查员赠款(涉及81个次级项目/核心)和61项培训 以及奖学金。在过去的资助中，DCI成员发表了5750多篇以癌症为重点的论文 期间，其中约40%代表DCI调查人员之间的合作努力。平均约7,000个新客户 每年都有癌症患者在杜克大学医院就诊。2018年，DCI项目注册人数超过4,000人 正在进行临床试验的患者，包括近2000名干预应计项目和770项治疗应计项目。DCI是 积极参与社区外展/参与和教育下一代癌症临床医生 还有科学家。Duke Health对DCI的支持包括总共超过6500万美元的额外投资 最近的资助期，包括对DCI教师的招聘、保留和受保护的学术时间的支持。 DCI完成了一个广泛的5年战略规划过程，确定了以下战略目标和优先事项 使疾病预防控制中心的使命“发现、开发和交付癌症护理…的未来”现在“，导致了一系列 作为确定当前和未来资源分配的指南的离散建议， 招聘优先事项，以及实现DCI目标所需的基础设施改革。